Skip to content

Investor Relations / Publications

Publications

The following publications, posters and citations are provided for investors and should not be construed as marketing the use of any Amarin products or product candidates. Copyright to certain documents referenced below are held by their publishers. Where possible, a link is provided for access to further information about the respective publication. Note that AMR101 is the clinical name for VASCEPA® (icosapent ethyl) capsules. For more information about VASCEPA® (icosapent ethyl) capsules visit www.vascepa.com.

For categorization of papers that support correlation between TG levels and CV risk, click here.

 

This page was last updated on September 9, 2020.

copyright
© 2021, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
Spaces South Docklands
Block C
77 Sir John Rogerson's Quay
Dublin 2, D02 VK60
Investor Relations
AMARIN CORPORATION PLC C/O AMARIN PHARMA, INC.
440 ROUTE 22
BRIDGEWATER, NJ 08807
investor.relations@amarincorp.com
Fax:
+1 908 719 3012

Amarin Corporation